Vevo
Ian Lai is a Research Scientist specializing in Cancer Biology at Vevo Therapeutics since June 2023, where collaboration with cross-functional teams and management of preclinical studies are key responsibilities. Prior experience includes serving as Head of Animal Science at D2G Oncology, leading reverse translation studies and developing proprietary software to enhance vivarium efficiency. At Stanford University School of Medicine, Ian held roles as a Basic Life Research Scientist and a Life Science Research Professional, where leadership in translational projects and expertise in immuno-oncology research were prominent. Ian began an academic career as a Postdoctoral Researcher at the University of Iowa, following the attainment of a Ph.D. in Human Toxicology and a Bachelor’s Degree in Biology from UC Irvine.
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.